Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Fintel on MSN
Structure Therapeutics Inc. - Depositary Receipt (GPCR) price target increased by 21.89% to 94.31
The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to $94.31 / share. This is an increase of 21.89% from the prior estimate of $77.
We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...
G-protein coupled receptors (GPCRs) are proteins triggered by ligands (protein-binding chemicals) from outside cells to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback